Column
Healthcare holds its own amid a tepid deal market , reaching $ 60 billion in announced deal value
Bain & Company ’ s Global Healthcare Private Equity Report shows how AI and innovative new therapies , such as GLP-1s , are transforming the investment landscape
NEW YORK — January 3 , 2024 — The healthcare sector continued to be a hub of private equity ( PE ) deal activity in 2023 , reaching $ 60 billion in announced deal value , despite higher global interest rates , in�ationary pressures , and broader geopolitical uncertainty . Biopharma captured the bulk of dealmaking momentum , attributing for 48 % of global deal value , including six deals in excess of $ 2 billion . In 2024 , investors will continue to bet on the transformative nature of generative AI ; new modalities and innovative therapies , such as glucagon-like peptide-1 agonists ( GLP-1s ); and India as a place to deploy healthcare capital at scale .
These are among the findings of Bain � Company ’ s 13th annual Global Healthcare Private Equity Report , published today .
�Compared to private e�uity dealmaking globally , we saw relative resilience in healthcare dealmaking last year ,” said Kara Murphy , co-lead of Healthcare �rivate ��uity at Bain � Company . ��e suspect 2024 will be a year of playing catch up , as buyers and sellers work toward bridging the valuation gap . Innovation and technology will continue to be at the forefront of investment themes across the value chain . Investors should carefully consider the evolving role of AI , the impacts of GLP-1 , and the growth of valuebased care on their portfolio companies and new investments .”
Regional perspectives : India ’ s age of healthcare is here In the Asia-�acific region , announced deal value
66 ISSUE 6 | 2023 GlobalHealthAsiaPacific . com